Renal Cell Carcinoma
636
85
150
258
Key Insights
Highlights
Success Rate
73% trial completion
Published Results
128 trials with published results (20%)
Research Maturity
258 completed trials (41% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
15.1%
96 terminated out of 636 trials
72.9%
-13.7% vs benchmark
6%
36 trials in Phase 3/4
50%
128 of 258 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 258 completed trials
Clinical Trials (636)
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
Identification and Description of Patients With High-risk Non Metastatic RCC
Transplantation of Reconstructed Renal Allografts Following Ex-Vivo Partial Nephrectomy
IDOV-Immune for Advanced Solid Tumors
PET/MR for Characterization of Renal Masses (RMs)
GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Use of Tracking Devices to Locate Abnormalities During Invasive Procedures
Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer
Anti-CD70-CAR-T Cell Injection for the Treatment of Locally Advanced or Relapsed/Metastatic CD70+ Inoperable Renal Cells
Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders
Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)